Skip to main content

People in the News: RainDance Names Merriweather CFO; QuantiBact Renamed Anapa, Appoints New CEO

Premium

RainDance Technologies said this week that Alfred Merriweather has joined the company as CFO.

Merriweather brings more than 25 years of executive level experience in private and public company financing, initial public offerings, mergers and acquisitions, as well as broad transactional experience in strategic corporate partnerships and initial public offerings, RainDance said. He most recently served as CFO of Verinata Health prior to its acquisition by Illumina. Previously he served as CFO and in senior executive positions with several leading life science and clinical diagnostics companies, including Celera and Monogram Biosciences.


Danish biotech company QuantiBact said recently that it has been renamed Anapa Biotech and has appointed Søren Morgenthaler Echwald as CEO. Echwald replaces Palle Schelde, who is leaving for a new job in the biotech industry.

Echwald joins Anapa from Exiqon, where he served as vice president of business development.

Anapa Biotech was founded in 2002 to develop products for microbiology and bacterial quantification. The company said that it has made "significant developments" in the past few years shaping its technologies for genomic applications in diagnostics and life sciences. As CEO, Echwald will lead Anapa in the process of commercializing these new technologies, the company said.

Echwald's experiences "perfectly match Anapa Biotech's strategy to grow partnerships with international companies within the diagnostics and life science industries," Patrik Dahlen, chairman of Anapa's board, said in a statement.

Filed under

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.